Chemotherapy of metastatic colon cancer in France: A population-based study. Issue 10 (October 2021)

• Record Type: Journal Article
• Authors: Mas, Léo; Bachet, Jean-Baptiste; Jooste, Valérie; Lepage, Côme; Bouvier, Anne-Marie
• Is Part Of: Digestive and liver disease. Volume 53:Issue 10(2021)
• Page Start: 1334
• Page End: 1342
• Publication Date: 2021-10
• Subjects: Metastatic colorectal cancer -- Chemotherapy -- Population-based; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2021.03.019
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Aims: to describe, using data from a cancer registry in a well-defined French population, the therapeutic strategies and survival of patients with metastatic colon cancer (mCC). Methods: all patients with synchronous mCC diagnosed within the 2005–2014 period recorded in the digestive cancers registry of Burgundy were included. Results: 1286 mCC patients were included (57% male), of which 34.5% did not receive any antitumor treatment. Both, advanced age (≥75 years) and the Charlson comorbidity score ≥2 were significantly associated with the absence of antitumor treatment. Among the patients treated with chemotherapy, 59 and 33% received at least two and three lines, respectively. Most patients treated with chemotherapy (68%) did not receive first-line targeted therapy. Of patients aged ≥75 years, 57% received no chemotherapy and 56% of treated patients had first-line treatment only. Conclusion: this population-based study shows that more than one-third of patients with mCC receive no chemotherapy and that only 59% of treated patients receive treatment beyond the first line. This study also highlights the fact that more than half of patients ≥75 years do not get any antitumor treatment. In patients <75 years, the proportion of patients receiving chemotherapy and/or undergoing curative intent surgery tended to increase over time.